XBIO - Xenetic Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Xenetic Biosciences, Inc.

99 Hayden Avenue
Suite 230
Lexington, MA 02421
United States
781-778-7720
http://www.xeneticbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey F. EisenbergCEO, Pres & Director318.33kN/A1966
Mr. James F. ParslowCFO, COO & Corp. Sec.287.6kN/A1965
Dr. Curtis A. LockshinChief Scientific Officer259.58kN/A1960
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Xenetic Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Its proprietary drug development platform, PolyXen, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company has a research, development, license, and supply agreements with Shire plc, Serum Institute of India, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts.

Corporate Governance

Xenetic Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.